🚀 VC round data is live in beta, check it out!
Hugel Valuation Multiples
Discover revenue and EBITDA valuation multiples for Hugel and similar public comparables like Lotus Pharmaceutical, Sionna Therapeutics, Cheezheng Tibetan Medicine, Pharma Mar and more.
Hugel Overview
About Hugel
Hugel Inc is a biopharmaceutical company. It is in the business of manufacturing of biopharmaceuticals. The company's primary products are Botulinum toxin, Hyaluronic acid filler, and Cosmetics. It develops and promotes its products under the brand name of Wellage. The firm has manufacturing facilities in Shinbuk and Geodu.
Founded
2001
HQ
Employees
N/A
Website
Financials (LTM)
EV
$2B
Hugel Financials
Hugel reported last 12-month revenue of $308M and EBITDA of $153M.
In the same LTM period, Hugel generated $242M in gross profit, $153M in EBITDA, and $101M in net income.
Revenue (LTM)
Hugel P&L
In the most recent fiscal year, Hugel reported revenue of $293M and EBITDA of $151M.
Hugel expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $308M | XXX | $293M | XXX | XXX | XXX |
| Gross Profit | $242M | XXX | $227M | XXX | XXX | XXX |
| Gross Margin | 79% | XXX | 78% | XXX | XXX | XXX |
| EBITDA | $153M | XXX | $151M | XXX | XXX | XXX |
| EBITDA Margin | 50% | XXX | 52% | XXX | XXX | XXX |
| EBIT Margin | 45% | XXX | 47% | XXX | XXX | XXX |
| Net Profit | $101M | XXX | $97M | XXX | XXX | XXX |
| Net Margin | 33% | XXX | 33% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Hugel Stock Performance
Hugel has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Hugel's stock price is $182.35.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $8.98 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHugel Valuation Multiples
Hugel trades at 5.3x EV/Revenue multiple, and 10.6x EV/EBITDA.
EV / Revenue (LTM)
Hugel Financial Valuation Multiples
As of April 19, 2026, Hugel has market cap of $2B and EV of $2B.
Equity research analysts estimate Hugel's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hugel has a P/E ratio of 19.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 5.3x | XXX | 5.5x | XXX | XXX | XXX |
| EV/EBITDA | 10.6x | XXX | 10.7x | XXX | XXX | XXX |
| EV/EBIT | 11.6x | XXX | 11.7x | XXX | XXX | XXX |
| EV/Gross Profit | 6.7x | XXX | 7.1x | XXX | XXX | XXX |
| P/E | 19.6x | XXX | 20.3x | XXX | XXX | XXX |
| EV/FCF | 18.2x | XXX | 18.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Hugel Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Hugel Margins & Growth Rates
Hugel's revenue in the last 12 month grew by 18%.
Hugel's rule of 40 is 64% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hugel's rule of X is 90% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Hugel Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | 50% | XXX | 52% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 3% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 64% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 90% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 3% | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 45% | XXX | 46% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Hugel Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Nutraceuticals & Cosmeceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Hugel | XXX | XXX | XXX | XXX | XXX | XXX |
| Lotus Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Sionna Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cheezheng Tibetan Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharma Mar | XXX | XXX | XXX | XXX | XXX | XXX |
| Trevi Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hugel M&A Activity
Hugel acquired XXX companies to date.
Last acquisition by Hugel was on XXXXXXXX, XXXXX. Hugel acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Hugel
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHugel Investment Activity
Hugel invested in XXX companies to date.
Hugel made its latest investment on XXXXXXXX, XXXXX. Hugel invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Hugel
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Hugel
| When was Hugel founded? | Hugel was founded in 2001. |
| Where is Hugel headquartered? | Hugel is headquartered in South Korea. |
| Is Hugel publicly listed? | Yes, Hugel is a public company listed on Korea Exchange. |
| What is the stock symbol of Hugel? | Hugel trades under 145020 ticker. |
| When did Hugel go public? | Hugel went public in 2015. |
| Who are competitors of Hugel? | Hugel main competitors are Lotus Pharmaceutical, Sionna Therapeutics, Cheezheng Tibetan Medicine, Pharma Mar. |
| What is the current market cap of Hugel? | Hugel's current market cap is $2B. |
| What is the current revenue of Hugel? | Hugel's last 12 months revenue is $308M. |
| What is the current revenue growth of Hugel? | Hugel revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of Hugel? | Current revenue multiple of Hugel is 5.3x. |
| Is Hugel profitable? | Yes, Hugel is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hugel? | Hugel's last 12 months EBITDA is $153M. |
| What is Hugel's EBITDA margin? | Hugel's last 12 months EBITDA margin is 50%. |
| What is the current EV/EBITDA multiple of Hugel? | Current EBITDA multiple of Hugel is 10.6x. |
| What is the current FCF of Hugel? | Hugel's last 12 months FCF is $89M. |
| What is Hugel's FCF margin? | Hugel's last 12 months FCF margin is 29%. |
| What is the current EV/FCF multiple of Hugel? | Current FCF multiple of Hugel is 18.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.